---
title: 'Funding Daily Summary: What Happened on October 26, 2026'
headline: Pathos AI raises $237 million to advance cancer pipeline
description: UK biotech companies raised £421 million in equity during the third quarter,
  bringing their 2026 total to £2.8 billion.
url: https://thebench.bio/news/funding/2026-10-26
topic: funding
date: '2026-10-26'
covers:
- '2026-10-26'
date_published: '2026-10-26T12:03:13Z'
date_modified: '2026-10-26T12:03:13Z'
tags:
- Funding
- Industry
sources: 2
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on October 26, 2026

**Pathos AI raises $237 million to advance cancer pipeline**

UK biotech companies raised £421 million in equity during the third quarter, bringing their 2026 total to £2.8 billion.

## Today in brief

Pathos AI raised $237 million in a Series E led by Bristol Myers Squibb, putting its post-financing valuation at about $3 billion. [1] UK biotech companies raised £421 million in equity in the third quarter, bringing their total for the first nine months of 2026 to £2.8 billion. [2]

## Pathos AI raises $237 million for cancer programs

Pathos AI raised $237 million in a Series E led by Bristol Myers Squibb, with existing investors also participating. [1] The financing valued the company at about $3 billion after the investment. [1]

Pathos plans to use the proceeds to expand Foundry, its platform for assessing biological, clinical, genomic and competitor information, and advance four active cancer programs. [1] Its clinical assets include AZD4241, developed with AstraZeneca, and DO-2. [1] Pathos is preparing JSKN016 for registrational trials and developing pocenbrodib for prostate cancer and multiple myeloma. [1]

Pathos raised $365 million in a Series D round in May 2025. [1]

## UK biotech raises £2.8 billion through the third quarter

UK biotech companies raised £421 million in equity in the third quarter of 2026, up 113% from the same quarter in 2025. [2] Venture capital made up £270 million of the total, a 44% year-on-year increase. [2]

The third-quarter venture-capital total was below the £2.05 billion raised in the second quarter, which included Isomorphic Labs’ £1.6 billion Series B. [2] By the end of the third quarter, UK biotech had raised £2.8 billion in 2026, more than in any full year from 2022 through 2025. [2]

The BioIndustry Association said the sector could record its highest annual venture-capital total since 2021. [2]

## The day in numbers

- **$237 million**: Pathos AI’s Series E financing [1]
- **£421 million**: UK biotech total equity raised in the third quarter of 2026 [2]
- **£2.8 billion**: UK biotech funding raised through the first three quarters of 2026 [2]

## Sources

1. [Pathos AI completes $237m Series E round to expand oncology pipeline](<https://www.pharmaceutical-technology.com/news/pathos-ai-237m-expand-oncology-pipeline/>), Pharmaceutical Technology, 2026-10-26
2. [UK biotech poised for record VC year after maintaining recovery momentum](<https://www.pharmaceutical-technology.com/news/uk-biotech-poised-for-record-vc-year-after-maintaining-recovery-momentum/>), Pharmaceutical Technology, 2026-10-26

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/pathos-ai-237m-expand-oncology-pipeline/>
[2]: <https://www.pharmaceutical-technology.com/news/uk-biotech-poised-for-record-vc-year-after-maintaining-recovery-momentum/>